Aligos Therapeutics, Inc. - Common Stock par value, $0.0001 per share (ALGS)

CUSIP: 01626L204

Q2 2025 13F Holders as of 30 Jun 2025

Holder snapshot 6 signals
Share change
-591,208
SEC-reported price per share
$7.21
Number of holders
37
Value change
-$4,851,101
Number of buys
17
Number of sells
15
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
6,260,327

Security key

01626L204

Report period

Q2 2025

Institutions

37

Top holders

10

Ownership snapshot

Top reported holders of ALGS - Aligos Therapeutics, Inc. - Common Stock par value, $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Alyeska Investment Group,...
Disclosed value leader
ADAGE CAPITAL PARTNERS GP...
Comparable rows
4/15
Latest evidence
30 Jun 2025
13F 13D/G 3/4/5 Lead comparable stake: 10% 11 rows are not safely comparable across share classes. 13D/G row: Alyeska Investment Group, L.P. Showing 1-6 of 15 holder rows.

Quick read

Alyeska Investment Group, L.P. leads the comparable SEC ownership view at 10%.

4 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Alyeska Investment Group, L.P.'s linked filing trail.
Comparable ownership Top 4
Alyeska Investment Group, L.P. 10%
ARMISTICE CAPITAL, LLC 5%
Adage Capital Management, L.P. 3.9%
EcoR1 Capital, LLC 3.9%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Alyeska Investment Group, L.P.
13F 13D/G
Company
10%
Reported 13D/G · 31 Mar 2025
$3,399,000
412,000 shares
— 31 Mar 2025
ARMISTICE CAPITAL, LLC
13D/G
5%
Reported 13D/G · 31 Dec 2024
$998,721
188,438 shares
$0 31 Dec 2024
Adage Capital Management, L.P.
13D/G
3.9%
Reported 13D/G · 30 Jun 2025
$1,514,100
210,000 shares
-$829,150 30 Jun 2025
EcoR1 Capital, LLC
13D/G 13F
Company
3.9%
Reported 13D/G · 31 Mar 2025
$1,116,360
210,634 shares
$0 31 Mar 2025
ROCHE HOLDING LTD
3/4/5
10%+ Owner
—
denominator unverified
—
11,025,941 shares
— 25 Oct 2023
ADAGE CAPITAL PARTNERS GP, L.L.C.
13F
Company
13F
—
denominator unverified
$3,836,250
465,000 shares
— 31 Mar 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
37
Shares
2,706,213
Rows available
37
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2025 vs Q2 2026 Across Filers

Q2 2026 holders
31
Q2 2025 holders
37
Holder diff
6
Investor Q2 2026 Shares Q2 2025 Shares Share Diff Share Chg % Q2 2026 value Q2 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .